S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
A $226B Copper Spending Jackpot (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
A $226B Copper Spending Jackpot (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
A $226B Copper Spending Jackpot (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
A $226B Copper Spending Jackpot (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
A $226B Copper Spending Jackpot (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
A $226B Copper Spending Jackpot (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
A $226B Copper Spending Jackpot (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
A $226B Copper Spending Jackpot (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
A $226B Copper Spending Jackpot (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
A $226B Copper Spending Jackpot (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
A $226B Copper Spending Jackpot (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
A $226B Copper Spending Jackpot (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
NASDAQ:RGEN

Repligen - RGEN Price Target & Analyst Ratings

$178.84
+11.35 (+6.78%)
(As of 11/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$167.80
$181.57
50-Day Range
$167.03
$220.56
52-Week Range
$137.21
$299.49
Volume
3.11 million shs
Average Volume
559,531 shs
Market Capitalization
$9.93 billion
P/E Ratio
61.67
Dividend Yield
N/A
Price Target
$249.80

Repligen Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 5 Analyst Ratings

Consensus Analyst Price Target

$249.80
39.68% Upside
High Prediction$275.00
Average Prediction$249.80
Low Prediction$213.00
TypeCurrent
12/1/21 to 12/1/22
1 Month Ago
11/1/21 to 11/1/22
3 Months Ago
9/2/21 to 9/2/22
1 Year Ago
12/1/20 to 12/1/21
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
4 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$249.80$254.40$276.00$316.86
Predicted Upside39.68% Upside18.72% Upside17.74% Upside17.84% Upside
Get Repligen Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter.


RGEN Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RGEN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Repligen Stock vs. The Competition

TypeRepligenMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.66
2.48
Consensus RatingBuyBuyHold
Predicted Upside39.68% Upside576.52% Upside11.47% Upside
News Sentiment RatingPositive News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
385
69.37%
Underperform Votes
170
30.63%
Avg. Outperform Votes
164
66.40%
Avg. Underperform Votes
83
33.60%
Avg. Outperform Votes
853
68.13%
Avg. Underperform Votes
399
31.87%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/2/2022William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Larew
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
11/2/2022Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$274.00 ➝ $251.00+35.27%
8/3/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$220.00 ➝ $250.00+2.99%
8/3/2022Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$220.00 ➝ $275.00+15.85%
8/3/2022KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$245.00 ➝ $260.00+9.53%
7/20/2022UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$213.00+26.73%
10/14/2021Exane BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$330.00+26.01%
5/5/2021HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$225.00 ➝ $240.00+23.29%
5/27/2020Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetPositive ➝ Buy$135.00 ➝ $150.00+7.52%
(Data available from 12/1/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












RGEN Price Target - Frequently Asked Questions

What is Repligen's consensus rating and price target?

According to the issued ratings of 5 analysts in the last year, the consensus rating for Repligen stock is Buy based on the current 5 buy ratings for RGEN. The average twelve-month price prediction for Repligen is $249.80 with a high price target of $275.00 and a low price target of $213.00. Learn more on RGEN's analyst rating history.

Do Wall Street analysts like Repligen more than its competitors?

Analysts like Repligen more than other Medical companies. The consensus rating score for Repligen is 3.00 while the average consensus rating score for medical companies is 2.66. Learn more on how RGEN compares to other companies.

Do MarketBeat users like Repligen more than its competitors?

MarketBeat users like Repligen more than other Medical companies. 69.37% of MarketBeat users gave Repligen an outperform vote while medical companies recieve an average of 66.40% outperform votes by MarketBeat users.

Does Repligen's stock price have much upside?

According to analysts, Repligen's stock has a predicted upside of 14.90% based on their 12-month price targets.

What analysts cover Repligen?

Repligen has been rated by Craig Hallum, and William Blair in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:RGEN) was last updated on 12/1/2022 by MarketBeat.com Staff